Ned Bittinger

The Business Side of Art

This content shows Simple View

Cancer Research

Plight of Dr. Clay Siegall

Most successful people didn’t start out success in life. For most of these individuals, failure was not an option. It takes patience as well as perseverance when trying to reach your goals and like the old saying goes, “Rome Wasn’t Built In A Day.” The fact is truly this and only this; anything worth having is worth working hard for. Unless you’re born into a wealthy family and just randomly hit the lottery, there will surly indeed be some form of plight to get you where you want to be. Clay Siegall is one of the most well respected individuals in cancer research. This guy has done it all as well as seen it all. Cancer has a way of bringing the best out of people especially those who are doing all they can to eradicate the illness.

Dr. Clay Siegall is at the of his game and has a huge level of success to back up all claims. With a (BS) in Zoology from The University of Maryland and a Ph.D from George Washington University, he has taken Seattle Genetics straight to the top. Seattle Genetics is huge with while holding an 800+ employee base. The growth of this company is that it produces the highest quality of cancer medications. The medications that are known as antibody drug conjugates, yield a much higher success rate than previous medications of the past. Dr. Siegall has built a solid foundation that stands by drug development, scientific innovation, and thorough research. There is no room for error when a person’s life is at stake and this company firmly stands by those principles.

As of 2015, Seattle Genetics has racked up over $226 Million from it’s (ADCETRIS) drug alone. This is just in Canada and the U.S. Expectations for the following year is somewhere between $250-$275 Million as this goes to show just how important these breakthrough therapies really are. Though Clay Siegall has come along way, he’s looking to take this company even farther in the years to come.